Sign In

Philomena Kamya

Director at Johnson & Johnson

Philomena Kamya, Ph.D. is a healthcare and biotech investment professional currently serving as a Director at Johnson & Johnson, a position she has held since September 2020.1 She has an extensive background in both academia and industry, with expertise in immunology, biotechnology, and finance.

Career Highlights

  • Current Role: Director at Johnson & Johnson (September 2020 - Present)1
  • Previous Positions:
    • Venture Partner at Elm Street Ventures (June 2019 - August 2020)
    • Portfolio Management at BridgeBio (May 2018 - June 2019)
    • Biotechnology Equity Research at Stifel Financial Corp. (June 2015 - May 2018)1

Education

  • Ph.D. in Immunology from McGill University (2004 - 2011), with a GPA of 3.98/4.01
  • Postdoctoral Fellowship in Immunology at Harvard Medical School (2011 - 2015)1

Additional Qualifications

  • Holds Series 7, Series 87, and Series 86 licenses from the Financial Industry Regulatory Authority (FINRA)1
  • Member of the National Venture Capital Association1
  • Bilingual proficiency in French and English1

Philomena Kamya's diverse experience spans academic research, venture capital, portfolio management, and biotechnology equity research, making her a well-rounded professional in the healthcare and biotech investment sector.12

Highlights

The Breadth of Expandable Memory CD8+ T Cells Inversely ...

Related Questions

What are Philomena Kamya's main responsibilities at Johnson & Johnson?
How did Philomena Kamya transition from academia to industry?
What are some notable projects Philomena Kamya has worked on at Johnson & Johnson?
How has Philomena Kamya's background in immunology influenced her career in biotechnology?
What are the key achievements of Philomena Kamya in her career so far?
Philomena Kamya
Philomena Kamya, photo 1
Philomena Kamya, photo 2
Add to my network

Location

New York, New York, United States